René Maltais

ORCID: 0000-0002-0394-1653 · 8 papers in corpus
lab-animal 2023
Molecules (Basel, Switzerland) ·doi:10.3390/molecules28020632

Estradiol (E2) plays an important role in the progression of diseases such as breast cancer and endometriosis. Inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), the enzyme that catalyzes the last step in the biosynthesis of …

rct 2022
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2022.106136

Endometriosis is a gynecological disorder affecting about 10% of women and can lead to invalidating painful symptoms and infertility. Since there is no current definitive cure for this disease, new therapeutic options are necessary. 17β-Hyd…

lab-animal 2021
Cancers ·doi:10.3390/cancers13081841

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) plays an important role in estrogen-dependent breast tumor growth. In addition to being involved in the production of estradiol (E2), the most potent estrogen in women, 17β-HSD1 is also res…

lab-animal 2021
Steroids ·doi:10.1016/j.steroids.2021.108856

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) and steroid sulfatase (STS) are involved in the synthesis of the most potent estrogen in the human body, estradiol (E2). These enzymes are known to play a pivotal role in the progression of…

lab-animal 2018
Steroids ·doi:10.1016/j.steroids.2018.09.009

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a promising therapeutic target known to play a pivotal role in the progression of estrogen-dependent diseases such as breast cancer, and endometriosis. This enzyme is responsible for the…

lab-animal 2017
Biochemical pharmacology ·doi:10.1016/j.bcp.2017.08.004

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) is involved in the biosynthesis of estradiol, the major bioactive endogenous estrogen in mammals, and constitutes an interesting therapeutic target for estrogen-dependent diseases. A steroi…

lab-animal 2017
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2017.12.007

The development of a covalent inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a promising approach for the treatment of hormone-dependent breast cancer and endometriosis. After reporting the steroid derivative PBRM as a f…

lab-animal 2011
ACS medicinal chemistry letters ·doi:10.1021/ml200093v

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) represents a promising therapeutic target for breast cancer treatment. To reduce the undesirable estrogenic activity of potent 17β-HSD1 inhibitor 16β-(m-carbamoylbenzyl)estradiol (1) (IC(50…